A Phase 3 clinical trial has reported that daraxonrasib, an experimental drug targeting RAS proteins, nearly doubled overall survival compared with standard chemotherapy in patients with pancreatic cancer, one of the most lethal and hard-to-treat malignancies.
A Difficult Disease
Pancreatic cancer is notorious for being diagnosed late and responding poorly to existing treatments, leaving patients with limited options and short survival times. Improving outcomes has been a persistent challenge in oncology, making meaningful gains in survival especially significant.
Many pancreatic tumors are driven by mutations in RAS genes, which have long been considered extremely difficult drug targets. Daraxonrasib belongs to a class of RAS inhibitors designed to interfere with this key cancer pathway.
The Phase 3 stage of testing is the most rigorous step before a treatment can seek approval, typically comparing a new therapy against the current standard of care in a large group of patients. A clear survival benefit at this stage is what regulators and physicians look for when weighing whether a drug should become widely available.
Trial Results
- Survival gain: Median overall survival rose from 6.7 months with standard chemotherapy to 13.2 months with the drug.
- Strong statistics: The trial reported a hazard ratio of 0.40, with a highly significant p-value of less than 0.0001.
- Targeted approach: The benefit came from inhibiting RAS, a driver mutation common in pancreatic tumors.
Why RAS Matters
RAS proteins act as switches that help control cell growth. When mutated, they can become stuck in an active state, driving uncontrolled division. For decades these proteins were viewed as nearly impossible to block with drugs, earning a reputation as "undruggable." Recent advances have begun to change that, and the pancreatic cancer results add to evidence that targeting RAS can translate into clinical benefit.
The drug is among several RAS inhibitors being evaluated across cancer types as researchers work to exploit this long-elusive target.
Context and Caution
The pancreatic cancer result is part of a broader wave of cancer research progress reported in 2026, alongside trials exploring approaches such as high-dose vitamin B3 for the aggressive brain cancer glioblastoma.
As with any single trial, experts note several caveats:
- Results must be confirmed and reviewed in full, including details on side effects and quality of life.
- Regulatory evaluation determines whether and when a treatment becomes widely available.
- Benefits seen in a trial population may vary across the broader patient community.
Even with those caveats, a near-doubling of median survival in pancreatic cancer represents a notable signal in a field where progress has been hard won.
The result also reflects a broader shift in cancer treatment toward therapies aimed at the specific genetic drivers of a tumor rather than broad chemotherapy alone. If RAS inhibitors continue to prove effective, they could expand the toolkit for one of medicine's toughest cancers and, potentially, for other RAS-driven tumors as well. Researchers will be watching follow-up data closely to see how durable the survival benefit proves over time.